Skip to content
Back to search results

Sinonasal Outcome Test-22

Introduced by
Claire Hopkins, King's College London
Year
2009
Type
Self-report questionnaire
Family
sino-nasal-qol
Font size

What does it do?

The SNOT-22 is a 22-item disease-specific quality-of-life questionnaire designed to assess sino-nasal symptoms and their functional impact on patients with chronic rhinosinusitis, nasal polyposis, and allied conditions.

Developed by Hopkins and colleagues at King's College London in 2009, it has become the most widely used instrument for measuring sino-nasal disease burden in clinical trials and rhinological practice. The SNOT-22 provides rapid, patient-centered assessment of both nasal-specific symptoms (congestion, drainage, sneezing) and general health impacts (sleep, headache, concentration).

The intuition behind the method

The SNOT-22 recognizes that sino-nasal disease extends beyond simple nasal symptoms. Chronic rhinosinusitis and nasal polyposis profoundly disrupt sleep, impair concentration, create headaches, and generate social embarrassment (e.g., nasal drainage, snoring). Patients experiencing these cascading effects often report worse quality of life than objective severity scores (endoscopy, imaging) would suggest. The SNOT-22 captures both direct nasal symptoms (congestion, postnasal drip, sneezing, loss of smell/taste) and systemic consequences (sleep disruption, headache, fatigue, social withdrawal, emotional distress). This comprehensive approach ensures clinicians understand the true patient burden and can counsel on expected treatment benefits.

History

Hopkins and colleagues at King's College London developed the SNOT-22 in 2009 as an extension of the original 20-item SNOT, refined for improved psychometric properties. The 22-item version received extensive validation in multinational studies (Kennedy et al. 2012) and has since become the de facto gold standard in rhinology. Translations exist in >15 languages. Domain-specific subscores have been proposed in some research but the unidimensional total score remains standard in clinical practice and trials.

When to use it

The SNOT-22 is indicated for patients with chronic rhinosinusitis (CRS), nasal polyposis, allergic rhinitis, or other chronic sino-nasal conditions. It is the preferred instrument in rhinological clinical trials, pre–post surgical efficacy studies, and subspecialty rhinology clinics. The SNOT-22 is less useful for acute sinusitis (where symptoms fluctuate rapidly) or primary care screening (use simpler allergic rhinitis tools instead). It has also been adapted for use in non-sino-nasal conditions (e.g., cystic fibrosis-related sinus disease).

Limitations and considerations

  • Potential for ceiling/floor effects in mild disease or complete remission: Minimal symptoms may yield non-informative low scores with limited discrimination
  • Item redundancy: Some overlapping content (e.g., multiple drainage-related items) limits statistical independence
  • Limited scope in acute settings: 22-item length may be excessive for acute exacerbation assessment; shorter instruments may be preferable

Source conditions do not replace independent scientific review or validation by an analysis engine.

Strengths

  • Disease-specific: All 22 items directly address sino-nasal symptoms and disease-relevant impacts; no generic filler items
  • Psychometrically rigorous: Demonstrates high internal consistency (Cronbach's α=0.95), strong test–retest reliability (ICC>0.9), and construct validity across multiple languages
  • Well-defined MCID: 8.9-point threshold provides objective benchmark for clinical improvement, essential for surgical decision-making and trial design
  • Rapid administration: 5–7 minute completion time facilitates routine clinic use; no specialist training required

Applications

  • Chronic rhinosinusitis trials: Primary endpoint in medical therapy studies (e.g., biofilm-targeting antibiotics, dupilumab efficacy); sensitive to pharmacological response
  • Endoscopic sinus surgery outcomes: Baseline assessment and 3–6-month post-operative measurement to quantify symptom improvement and surgical success
  • Allergic rhinitis management: Tracking seasonal allergen exposure impact and intranasal corticosteroid/antihistamine efficacy in chronic cases
  • Quality of life research: Population-level assessment of sino-nasal disease burden in epidemiological studies or health policy evaluation

How it works

How it works

1

The SNOT-22 comprises 22 items covering four domains: nasal symptoms (congestion, postnasal drip, loss of smell/taste, sneezing, runny nose), sleep (difficulty sleeping, awakening from sleep), general well-being (headache, facial pain, concentrating, remembering, fatigue, mood, embarrassment, frustration), and otologic symptoms (ear fullness, dizziness). Each item is rated on a 0–5 Likert scale (0='no problem' to 5='problem as bad as it can be'). The questionnaire is self-completed, typically requiring 5–7 minutes. No training or specialist interpretation is needed; respondents score their own experience.

Formula
Respondent rates 22 sino-nasal and general health symptoms on 0–5 Likert scale
2

SNOT-22 Total Score is the simple sum of all 22 items, yielding a continuous 0–110 scale (lower = better). No subscale calculation is required for the standard version, though research publications sometimes report domain-specific subscores for deeper analysis. The Minimum Clinically Important Difference (MCID) is 8.9 points; a change of ≥8.9 represents meaningful improvement or deterioration. For group-level studies, an MCID of 8–9 points is applied.

Formula
Individual item scores summed to yield total 0–110 score
3

SNOT-22 interpretation: 0–30 = mild sino-nasal burden, 31–60 = moderate burden, 61–90 = severe burden, >90 = very severe burden. Baseline SNOT-22 scores inform treatment intensity: patients scoring >70 typically warrant endoscopic sinus surgery or other interventions. Change scores are clinically paramount: a reduction of ≥8.9 points signals clinically meaningful improvement after medical or surgical therapy. Lack of improvement despite treatment may indicate inadequate diagnosis, poor adherence, or need for alternative therapy.

Formula
Higher scores indicate worse sino-nasal disease burden; MCID=8.9 points

Common pitfalls

  • Treating SNOT-22 score as surgical indication: A high score suggests symptom burden but does not automatically indicate need for surgery; endoscopic and imaging findings must align with symptoms
  • Ignoring domain interpretation: Reviewing only total score may mask specific problem areas (e.g., prominent sleep disruption vs. pain) that inform targeted treatment
  • Assuming MCID uniformly applies: The 8.9-point MCID is group-level; individual patient thresholds may vary; always contextualize within patient's baseline severity and goals

Frequently asked questions

Is SNOT-22 suitable for acute sinusitis, or only chronic rhinosinusitis?

SNOT-22 is designed for chronic conditions; acute sinusitis is self-limited and symptoms resolve quickly. For acute exacerbation assessment, simpler symptom diaries or visual analog scales are preferable. Use SNOT-22 in acute exacerbations of chronic CRS or when assessing CRS baseline prior to acute worsening.

A patient improves by 6 points on SNOT-22; is this clinically meaningful?

A 6-point improvement falls below the MCID threshold of 8.9 points, suggesting non-significant change at the group level. However, individual patient perception matters; if the patient reports meaningful symptom relief, clinical judgment trumps the cutoff. Always integrate SNOT-22 with objective findings and patient satisfaction.

How do I score SNOT-22 if the patient skips items?

Missing item handling varies by study protocol. Typically, if <5% of items are missing, the patient's mean item score can impute the missing value(s). If >5% are missing, the questionnaire is considered incomplete. Modern digital versions often enforce item completion to avoid this issue.

Should I use SNOT-22 or RQLQ for allergic rhinitis?

SNOT-22 is better for chronic rhinosinusitis and nasal polyps. RQLQ (Rhinoconjunctivitis QoL Questionnaire) is more sensitive for allergic rhinitis with eye symptoms. Consider disease phenotype: if predominantly nasal/sinus, use SNOT-22; if allergic rhinitis with ocular involvement, consider RQLQ.

Related methods

Sources

  1. Hopkins, C., Gillett, S., Slack, R., Lund, V. J., & Browne, J. P. (2009). Psychometric validity of the 22-item Sinonasal Outcome Test. Clinical Otolaryngology, 34(5), 447-454.

    Open DOI reference
    Copied.
  2. Kennedy, J. L., Hubbard, M. A., Huyett, P., Patanavanich, S., Gould, H. M., & Köller, D. Y. (2012). Sino-Nasal Outcome Test (SNOT-22): A multicenter validation study. Rhinology, 50(4), 359-363.

    Open publication reference
    Copied.